Table 3 Baseline Characteristics of the Intent-to-Treat Population
From: A clinical trial of enteral Levetiracetam for acute seizures in pediatric cerebral malaria
Levetiracetam (n = 23) | Usual Care (n = 21) (Phenobarbital) | P-value* | |
|---|---|---|---|
Age (mean months, SD) | 41.4 (10.6) | 41.8 (16.7) | 0.50 |
Sex (n, % male) | 13 (57%) | 7 (33%) | 0.14 |
Parasite count (mean parasite/μL, SD) | 214,613 (412,786) | 259,729 (314,098) | 0.62 |
Malaria retinopathy (n, % positive) | 16 (70%) | 12 (57%) | 0.35 |
Lactate (mean mmol/L, SD) | 5.4 (3.7) | 4.4 (3.3) | 0.43 |
Hemoglobin (mean gdL, SD) | 8.5 (3.5)* | 8.2 (1.5) | 0.41 |
Hematocrit (% packed cell volumte, SD) | 25.8 (11.1)* | 24.6 (5.0) | 0.63 |
Platelets (per μL, SD) | 163,450 (155,960)α | 134,430 (162,330) | 0.48 |
Any rescue benzodiazepine or paraldehyde prior to enrollment¥ | 8 (35%) | 6 (29%) | 0.76 |
Two doses | 4 (17%) | 2 (10%) | 0.66 |